24th Oct 2019 12:53
(Alliance News) - MaxCyte Inc on Thursday said it has initiated dosing in the third cohort of patients of its phase I clinical trial with the next higher cell dose of MCY-M11.
MCY-M11 is being evaluated in relapsed/refractory ovarian cancer and peritoneal mesothelioma.
The cell-based therapies and life sciences company said the move follows the completion of dosing of the second cohort of patients. The dose escalation trial is evaluating the safety and tolerability, as well as preliminary efficacy, of MCY-M11 administered intraperitoneally across a series of ascending dose-level cohorts, MaxCyte explained.
In the first two cohorts, the infusion of MCY-M11 has been well tolerated in all patients treated, the Maryland, US-headquartered company said.
"We are making significant progress with our lead chimeric antigen receptor therapeutic and our proprietary CARMA autologous cell therapy platform. Furthermore, the on-going trial continues to demonstrate the feasibility of our one-day cell therapy manufacturing process," said Claudio Dansky Ullmann, chief medical officer.
Dansky added: "We are very excited about the potential of MCY-M11 as a new, effective therapeutic in solid tumors where the majority of patients still have very limited treatment options."
MaxCyte shares were untraded in London on Thursday, last closing at 115.10 pence each.
By Evelina Grecenko; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
MaxCyte